Aktienanalyse zu Trupanion Inc (TRUP)TRUPTrupanion Inc

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland. It operates in the Financials sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Trupanion Inc is currently a hold. The stock is priced at $29.62, which is below the recent analyst targets of $32 and $29. The company reported a significant revenue growth of 11% year-over-year in Q2 2026, reaching $392.9 million, but it faces challenges such as a declining number of vet visits and increased competition. The RSI is at 41.23, indicating it is not yet oversold, which suggests caution in buying. The main risk is the forward P/E ratio of 1428.57, indicating potential overvaluation in a challenging market environment.

6 analysts cover TRUP: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.40.